References
- NIH Consensus Development Program. Osteoporosis Prevention, Diagnosis, and Therapy, 2000. Available at: http://consensus.nih.gov/2000/2000Osteoporosis111html.htm [Last accessed 7 September 2011]
- Orimo H, Nakamura T, Shiraki M, et al. Japanese Guideline for the Prevention and Treatment of Osteoporosis 2006 Edition [in Japanese]. Tokyo: Life Science Publishing, 2006
- Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(Suppl):S1-34
- Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
- Hodgson SF, Watts NB, Bilezikian JP, et al. AACE Osteoporosis Task Force American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64
- Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010;21:1657-80
- Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404-15
- Kane S, Borisov NN, Brixner D. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Manag Care 2004;10:S216-26
- Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21
- Shiraki M, Yamazaki Y, Kuroda T, et al. Serum level of pepsinogen significantly associated with gastric distress induced by amino-bisphosphonate. Osteoporosis Int 2011;22:1717-23
- Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications. Problems, consequences and management strategies. Drugs Aging 2007;24:37-55
- Lichtenberger LM, Romero JJ, Gibson GW, et al. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 2000;45:1792-801
- Bauss F, Russell RGG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423-33
- Gasser JA, Green JR. Long-term protective effect of a single IV injection of zoledronic acid on cancellous bone structure and cortical bone in ovariectomized rats. Bone 2002;30(Suppl):41S
- Orimo H, Hayashi Y, Fukunaga M, et al. Osteoporosis diagnostic criteria review committee: Japanese society for bone mineral research. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001;19: 331-7
- Orimo H, Sugioka Y, Fukunaga M, et al. The committee of the Japanese society for bone and mineral research for development of diagnostic criteria of osteoporosis. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998;16:139-50
- Fukunaga M, Nakamura T, Shiraki M, et al. Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women. J Bone Miner Metab 2004;22:104-10
- Fukuhara S, Bito S, Green J, et al. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998;51:1037-44
- Fukuhara S, Ware JE, Kosinski M, et al. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998;51:1045-53
- Fukuhara S, Suzukamo Y. Manual of SF-36v2 Japanese version [in Japanese]. Kyoto: Institute for Health Outcomes & Process Evaluation Research, 2004
- Uchida S, Taniguchi T, Shimizu T, et al. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 2005;23:382-8
- Orimo H, Nakamura T, Fukunaga M, et al. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) – 02. Curr Med Res Opin 2011;27:1273-84
- Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-31
- Olson K, Poznak CV. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007;13:223-9